ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2022
Zinzino group revenue decreased with a total of 5%, compared with the previous year.
The revenue in February for Zinzino's sales markets decreased by 4% and amounted to SEK 88.5 (92.6) million. Faun Pharma's external sales decreased by 7% and amounted to SEK 6.3 (6.8) million. Overall, the Group decreased revenues by 5% to SEK 94.8 (99.4) million compared with the previous year.
Accumulated revenue for January – February 2022 decreased by 1% to SEK 204.5 (206.4) million.
Revenues were distributed as follows:
| Regions,MSEK | 22-Feb | 21-Feb | Change | YTD 2022 | YTD 2021 | Change |
| The Nordics | 21.1 | 27.6 | -24% | 47.2 | 58.5 | -19% |
| Central Europe | 18.4 | 16.8 | 10% | 36.9 | 35.2 | 5% |
| East Europe | 23.3 | 22.5 | 4% | 52.0 | 50.1 | 4% |
| South & West Europe | 11.3 | 9.9 | 14% | 23.7 | 20.0 | 19% |
| The Baltics | 5.1 | 5.6 | -9% | 11.7 | 11.3 | 4% |
| North America | 4.4 | 3.9 | 13% | 8.8 | 7.6 | 16% |
| Asia-Pacific | 4.5 | 6.3 | -29% | 10.2 | 11.6 | -12% |
| Africa | 0.4 | 0.0 | 0.8 | 0.0 | ||
| Zinzino | 88.5 | 92.6 | -4% | 191.3 | 194.3 | -2% |
| Faun Pharma | 6.3 | 6.8 | -7% | 13.2 | 12.1 | 9% |
| Zinzino Group | 94.8 | 99.4 | -5% | 204.5 | 206.4 | -1% |
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom, Belgium, Ireland
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge:
Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com
Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se
This disclosure contains information that Zinzino is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, at 16:00 the 3rd of March 2022.
Dag Bergheim PettersenCEO+46 (0) 31 771 71 50 shares@zinzino.comZinzino is a global D2C company from Scandinavia specializing in biomarkerbased, personalized nutrition.
Founded in 2005, it is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available on more than 100 markets
across the world. Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India, Taiwan and South Africa.